{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-009015","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.959782+00:00","generated_at":"2026-06-17T07:30:59.115763+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Windtree reports FY2022 net loss $39.2M; cash runway into Q2 2023 only","bullets":["Q4 2022 net loss $9.7M ($13.01/share); FY2022 net loss $39.2M ($62.23/share).","Operating loss Q4 $10.8M includes $6.8M rostafuroxin impairment; FY operating loss $41.3M includes $12.6M goodwill impairment.","Cash and equivalents $6.2M at Dec 31, 2022; expects to fund operations into Q2 2023 only.","Raised $1.0M from warrant exercises; R&D expense fell to $1.2M in Q4 from $4.5M YoY.","Istaroxime SEISMiC study met primary endpoint (p=0.017) in early cardiogenic shock; new patent for longer infusion."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-009015","json":"https://secwatch.observer/filing/0001437749-23-009015.json","markdown":"https://secwatch.observer/filing/0001437749-23-009015.md","text":"https://secwatch.observer/filing/0001437749-23-009015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/0001437749-23-009015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/wint20221118b_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:30:59.115763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d935643383a8c375f68cca41ab51a43ef34c4f0","claim":"WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On April 3, 2023, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/0001437749-23-009015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}